A Prospective Study for the Detection of Nephrogenic Systemic Fibrosis in Patients With Renal Impairment Undergoing Gadoversetamide-enhanced Magnetic Resonance Imaging

Trial Profile

A Prospective Study for the Detection of Nephrogenic Systemic Fibrosis in Patients With Renal Impairment Undergoing Gadoversetamide-enhanced Magnetic Resonance Imaging

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Gadoversetamide (Primary)
  • Indications Kidney disorders; Renal failure
  • Focus Diagnostic use; Registrational
  • Acronyms SHERLOC
  • Sponsors Mallinckrodt Medical
  • Most Recent Events

    • 20 Jul 2017 Planned End Date changed from 1 Feb 2013 to 17 May 2012.
    • 20 Jul 2017 Planned primary completion date changed from 1 Feb 2013 to 17 May 2012.
    • 20 Jul 2017 Status changed from suspended to withdrawn prior to enrolment.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top